To overcome concerns related to CRS, Liu et al. discovered that CAR-T therapy triggers IL-1β production and change macrophage phenotype via upregulation of PD-L1 and indoleamine 2,3-dioxygenase (IDO), thereby activating the AIM2 inflammasome and the α1-AR-mediated adrenergic pathway. This evidence concerns the gene AIM2 and congenital rubella syndrome.